Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00477529
What this trial is testing

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Celgene 102
Testing effectiveness (Phase 2)Study completedNCT00738673
What this trial is testing

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Ferring Pharmaceuticals 37
Testing effectiveness (Phase 2)UnknownNCT02691975
What this trial is testing

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Who this might be right for
Hormone Refractory Prostate CancerMetastatic Prostate Carcinoma
Jiangsu HengRui Medicine Co., Ltd. 197
Testing effectiveness (Phase 2)Study completedNCT00436956
What this trial is testing

AZD2171 to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 59
Testing effectiveness (Phase 2)Ended earlyNCT00879619
What this trial is testing

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Who this might be right for
Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer+3 more
John P. Fruehauf 4
Early research (Phase 1)Study completedNCT01837095
What this trial is testing

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Polyphor Ltd. 54
Testing effectiveness (Phase 2)Study completedNCT00331344
What this trial is testing

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 100
Post-approval studies (Phase 4)Study completedNCT00219219
What this trial is testing

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Who this might be right for
Prostate Cancer
Novartis
Testing effectiveness (Phase 2)Study completedNCT00748358
What this trial is testing

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic NeoplasmsNeoplasms, Hormone-DependentTumor Markers, Biological+2 more
Assistance Publique - Hôpitaux de Paris 50
Testing effectiveness (Phase 2)Study completedNCT00077402
What this trial is testing

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Cancer Therapeutics Research Group 50
Large-scale testing (Phase 3)Study completedNCT00003343
What this trial is testing

Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Pfizer 525
Not applicableStudy completedNCT01160705
What this trial is testing

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Who this might be right for
Metastatic CancerProstate Cancer
Cancer Trials Ireland 73
Early research (Phase 1)Study completedNCT00415779
What this trial is testing

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
National Cancer Institute, Naples 36
Testing effectiveness (Phase 2)Study completedNCT00046826
What this trial is testing

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Who this might be right for
Prostate Cancer
Nuvance Health
Testing effectiveness (Phase 2)Study completedNCT00085228
What this trial is testing

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC 116
Testing effectiveness (Phase 2)Study completedNCT00514267
What this trial is testing

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Who this might be right for
Prostate CancerTumors
Astellas Pharma Inc 32
Testing effectiveness (Phase 2)Study completedNCT00116155
What this trial is testing

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Cell Genesys
Early research (Phase 1)Study completedNCT01422850
What this trial is testing

Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Who this might be right for
Hormone-refractory Prostate Cancer
CytoVac A/S 21
Testing effectiveness (Phase 2)Study completedNCT00025116
What this trial is testing

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 40
Testing effectiveness (Phase 2)Study completedNCT01083368
What this trial is testing

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Who this might be right for
Prostate Cancer
Case Comprehensive Cancer Center 22
Next Page